P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Shaji Kumar,Jesus G. Berdeja,Ruben Niesvizky,Sagar Lonial,Jacob P. Laubach,Mehdi Hamadani,A. Keith Stewart,Parameswaran Hari,Vivek Roy,Robert Vescio,Jonathan L. Kaufman,Deborah Berg,Eileen Liao,Alessandra Di Bacco,Jose Estevam,Neeraj Gupta,Ai Min Hui,Vincent Rajkumar,Paul G. Richardson +18 more
TL;DR: The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was generally well tolerated and appeared active in newly diagnosed multiple myeloma, and these results support the phase 3 trial development of this combination for multipleMyeloma.
Journal ArticleDOI
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
Paul G. Richardson,Marcie L. Riches,Nancy A. Kernan,Joel A. Brochstein,Shin Mineishi,Amanda M. Termuhlen,Sally Arai,Stephan A. Grupp,Eva C. Guinan,Paul L. Martin,Gideon Steinbach,Amrita Krishnan,Eneida R. Nemecek,Sergio Giralt,Tulio E. Rodriguez,Reggie E. Duerst,John Doyle,Joseph H. Antin,Angela R. Smith,Leslie Lehmann,Richard E. Champlin,Alfred P. Gillio,Rajinder P.S. Bajwa,Ralph B. D'Agostino,Joseph M. Massaro,Diane Warren,Maja Miloslavsky,Robin Hume,Massimo Iacobelli,Bijan Nejadnik,Alison L. Hannah,Robert J. Soiffer +31 more
TL;DR: Defibrotide was associated with significant improvement in day +100 survival and CR rate and the historical-control methodology offers a novel, meaningful approach for phase 3 evaluation of orphan diseases associated with high mortality.
Journal ArticleDOI
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
Asher A. Chanan-Khan,Pieter Sonneveld,Michael W. Schuster,Edward A. Stadtmauer,Thierry Facon,Jean Luc Harousseau,Dina Ben-Yehuda,S. Lonial,Hartmut Goldschmidt,Donna E. Reece,Rachel Neuwirth,Kenneth C. Anderson,Paul G. Richardson +12 more
TL;DR: For patients treated with bortezomib or bortzomib-containing regimens, the risk of VZV reactivation should be monitored and routine use of antiviral prophylaxis considered.
Journal ArticleDOI
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Yu-Tzu Tai,Xian-Feng Li,Iris Breitkreutz,Weihua Song,Paola Neri,Laurence Catley,Klaus Podar,Teru Hideshima,Dharminder Chauhan,Noopur Raje,Robert L. Schlossman,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +13 more
TL;DR: A role for BAFF is established in localization and survival of multiple myeloma cells in the bone marrow microenvironment and strongly support novel therapeutics, targeting the interaction between BAFF and its receptors in human multipleMyeloma.
Journal ArticleDOI
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial
Paul G. Richardson,Robert J. Soiffer,Joseph H. Antin,Hajime Uno,Zhezhen Jin,Joanne Kurtzberg,Paul L. Martin,Gideon Steinbach,Karen F. Murray,Georgia B. Vogelsang,Allen R. Chen,Amrita Krishnan,Nancy A. Kernan,David Avigan,Thomas R. Spitzer,Howard M. Shulman,Donald N. Di Salvo,Carolyn Revta,Diane Warren,Parisa Momtaz,Gary Bradwin,L. J. Wei,Massimo Iacobelli,George B. McDonald,Eva C. Guinan +24 more
TL;DR: In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day was selected for ongoing phase III trials in VOD.